Pneumoconiosis
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Pneumoconiosis is an occupational lung disease caused by the inhalation of dust. Depending on the type of dust, variants of the disease are considered. Frequent types are asbestosis, coal miner’s lung, silicosis, and berylliosis. Rare types include siderosis, byssinosis, and talcosis. [1] Pneumoconiosis involve the particles causing irreversible lung damage and there is heavy emphasis on prevention through safety precautions at workplace settings. [2] To be qualified as a Pneumoconiosis or occupational disease there must be four criteria met. This includes documented exposure to the particle, a latent period before the development of symptoms, clinical signs and symptoms that entail the disease, and finally exclusion of other disease modalities. [3] There is no cure for the diseases and patients generally enter pulmonary rehabilitation programs and can become candidates for transplants during the end stages. [4] [5]
References
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help). - ↑ Epler GR (1992). “Clinical overview of occupational lung disease”. Radiol Clin North Am. 30 (6): 1121–33. PMID 1410303.
- ↑ Tsang EW, Kwok H, Chan AKY, Choo KL, Chan KS, Lau KS; et al. (2018). “Outcomes of community-based and home-based pulmonary rehabilitation for pneumoconiosis patients: a retrospective study”. BMC Pulm Med. 18 (1): 133. doi:10.1186/s12890-018-0692-7. PMC 6085700. PMID 30092783.
- ↑ Laney AS, Weissman DN (2014). “Respiratory diseases caused by coal mine dust”. J Occup Environ Med. 56 Suppl 10: S18–22. doi:10.1097/JOM.0000000000000260. PMC 4556416. PMID 25285970.
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Because the various pneumoconiosis present after exposure to specific particles and dust, their historical perspective varies according to the antigen. Generally, once patients began to present following exposure to a particle, safety measures and awareness followed.
Historical Perspective
Discovery
- There is evidence in ancient Egypt and Greece for a disease caused by silica inhalation. [1][2]
- Berylliosis was coined in 1946, when fluorescent lamp workers began presenting with pulmonary granulomatous diseases. [3]
Impact on Cultural History
- Many countries have banned the use of asbestosis and the United States has significantly decreased its use since the 1970s. [4]
- The UK limited its use of silica since 1949. [5]
References
- ↑ Brown HV (1965). “The history of industrial hygiene: a review with special reference to silicosis”. Am Ind Hyg Assoc J. 26 (3): 212–26. doi:10.1080/00028896509342723. PMID 5318957.
- ↑ Akira M (1995). “Uncommon pneumoconioses: CT and pathologic findings”. Radiology. 197 (2): 403–9. doi:10.1148/radiology.197.2.7480684. PMID 7480684.
- ↑ HARDY HL, TABERSHAW IR (1946). “Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds”. J Ind Hyg Toxicol. 28: 197–211. PMID 21000285.
- ↑ Wagner GR (1997). “Asbestosis and silicosis”. Lancet. 349 (9061): 1311–5. doi:10.1016/S0140-6736(96)07336-9. PMID 9142077.
- ↑ Wagner GR (1995). “The inexcusable persistence of silicosis”. Am J Public Health. 85 (10): 1346–7. doi:10.2105/ajph.85.10.1346. PMC 1615617. PMID 7573613.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Pneumoconiosis may be classified according to subtypes based on the particle of exposure. These can be fibrogenic, granulomatous, benign or hard metal: [1] [2]
- Fibrogenic: silica, coal, asbestos, talc
- Granulomatous: beryllium
- Benign: Iron, tin, barium
- Hard metal: cobalt
Classification
- Fibrogenic:
- Silicosis – silica
- Coalworker’s pneumoconiosis
- Asbestosis – asbestos fibers
- Talcosis – talc
- Granulomatous:
- Berylliosis – beryllium dust
- Benign:
- Siderosis – iron
- Hard metal pneumoconiosis
Pneumoconiosis in combination with multiple pulmonary rheumatoid nodules in rheumatoid arthritis patients is known as Caplan’s syndrome.[3] [4] [5]
References
- ↑ Akira M (1995). “Uncommon pneumoconioses: CT and pathologic findings”. Radiology. 197 (2): 403–9. doi:10.1148/radiology.197.2.7480684. PMID 7480684.
- ↑ Choi JW, Lee KS, Chung MP, Han J, Chung MJ, Park JS (2005). “Giant cell interstitial pneumonia: high-resolution CT and pathologic findings in four adult patients”. AJR Am J Roentgenol. 184 (1): 268–72. doi:10.2214/ajr.184.1.01840268. PMID 15615987.
- ↑ Andreoli, Thomas, ed. CECIL Essentials of Medicine. Saunders: Pennsylvania, 2004. p. 737.
- ↑ Stark P, Jacobson F, Shaffer K (1992). “Standard imaging in silicosis and coal worker’s pneumoconiosis”. Radiol Clin North Am. 30 (6): 1147–54. PMID 1410305.
- ↑ Baur X, Woitowitz HJ, Budnik LT, Egilman D, Oliver C, Frank A; et al. (2017). “Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update”. Am J Ind Med. 60 (5): 411–421. doi:10.1002/ajim.22709. PMID 28409857.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karol Gema Hernández, M.D. [2], Dushka Riaz, MD
Overview
Pneumoconiosis is an interstitial lung disease caused by the accumulation of different dust particles in the alveolar space. As the particles accumulate, the body’s elimination mechanisms begin to fail, resulting in activation of chemotactic factors that exacerbate the inflammatory response, and subsequently leading to fibrosis. [1]
Pathophysiology
Pathogenesis
The pathogenesis of pneumoconiosis starts with the inhalation of mineral, metallic or dust particles. The most common particles that cause pneumoconiosis are:
- Silica (quartz, cristobalite, coesite or tridymite silica polymorphs)
- Structural differences between the polymorphs of silica, are important because of the different degrees of biological reactivity they present, making some of them more toxic than others. The biological reactivity makes quartz more toxic, followed by tridymite, cristobalite, coesite, and finally stishovite. [3] [4] [5]
Other dust particles may also lead to pneumoconiosis, such as hydrated magnesium silicate, hydrous aluminum silicate, bauxite, cobalt, beryllium and iron. [6] [7]
Biological Reactivity of Different Dust Particles
Each dust particle has a different degree of biological reactivity. The dust particles ultimately cause inflammation, fibrosis and finally, irreversible lung disease. [1] This variability is due to properties in the surface of the particles. In the case of silica, there are two theories explaining their biological reactivity. One of them is that silica is a hydrogen donor, whereas biological macromolecules are hydrogen acceptors, creating strong hydrogen bonds that contribute to the damage. The other theory is that at a pH of 7.0 [3], silica is negatively charged, and therefore attracting alveolar macrophages, and activating the generation of reactive oxygen species and cytokines.
Shown below is a table summarizing the dust exposure associated with pneumoconiosis.
| Disease | Dust |
|---|---|
| Coal workers’ pneumoconiosis | Coal dust |
| Silicosis | Silica |
| Asbestosis | Asbestos |
| Talcosis | Hydrated aluminium silicate |
| Kaolin- induced pneumoconiosis | Hydrous aluminum silicate |
| Mixed dust pneumoconiosis | Coal dust, smoke from fires, and silicates |
| Aluminum- induced pneumoconiosis | Bauxite (Al2O3) |
| Berylliosis | Beryllium |
| Silicosiderosis | Silica and iron |
| Hard- metal disease (giant cell pneumonitis) | Cobalt |
When particles reach the distal lung, the mucociliary and lymphatic system take care of their elimination. Dust fibers must be less than 3 μm in diameter in order to penetrate the distal lung. Fibers greater than 5 μm are phagocytosed incompletely and retained in tissues. When particles increase in number, macrophages are activated to engulf those particles. Reticulin is then secreted by fibroblasts to entrap macrophages, as an attempt to control the excess of dust particles. [8]
The physiology of macrophage activation is subject to several theories. The macrophages are mainly derived from peripheral blood monocytes and, from local replication. The recruitment of monocytes from peripheral blood occurs in response to several chemotactic factors. Boitelle et al [9] suggest that one of the most potent chemotactic factors for peripheral blood monocytes is monocyte chemoattractant protein- 1 (MCP- 1), suggesting its role in chronic macrophage inflammation. TNFα activates MCP- 1 expression. MCP-1 is a 76 amino acid peptide that activates monocytes, and also increases its cytostatic activity and the expression of monocyte adhesion molecules such as CD11c/CD18 and CD11b/CD18.
As exposure continues, the elimination system begins to fail, leading to release of reactive oxygen species. These in turn exacerbates the inflammatory response, with the release of more cytokines, such as TNF and interleukins, which subsequently lead to fibrogenesis.
The determinants for the rate of disease progression are the accumulative dose; that is based in duration and intensity of exposure, the fiber type and individual susceptibility.
The underlying pathogenic mechanisms that lead to pulmonary fibrosis in pneumoconiosis remain unclear. Some studies in bronchoalveolar lavage made by Vanhée et al [10] suggest a potential protective effect of TGF- β on the development of pulmonary fibrosis. The alveolar macrophages in coal miners with massive fibrosis, secreted two main profibrotic factors; platelet-derived growth factor (PDGF) and insulin-like growth factor– 1 (IGF-1), whereas, the patients with simple pneumoconiosis secreted transforming- growth factor- β (TGF– β). This suggested a potential protective effect of TGF– β against the development of pulmonary fibrosis.
The risk for pneumoconiosis among constructions workers is evident, but Tjoe et al concluded there is not a clear-cut relationship between exposure and body’s response. This is complex due to the heterogeneity in exposure levels, as well as dust composition and the possible modification of toxicity by other factors present in dust.[11]
Shown below is an image depicting a lung affected with pneumoconiosis.
Genetics
Pneumoconiosis is caused by environmental exposure. However, acute and more severe forms of the disease do develop in more genetically susceptible people. For example, a study found polymorphism in IL‐1RA (+ 2018) may increase the risk for the development of silicosis. [12]
Associated Conditions
Conditions associated with pneumoconiosis include: [13]
- Asbestosis can cause malignant mesothelioma and bronchogenic carcinoma.
- Silicosis can exacerbate carcinoma and tuberculosis.
- Coal worker’s pneumoconiosis can increase the risk of tuberculosis.
Gross Pathology
On gross pathology, pleural plaques are characteristic findings of asbestosis as well as diffuse interstitial pulmonary fibrosis in reticular formation. Coal worker’s pneumoconiosis and silicosis both show small interstitial nodules in the upper lung. All pneumoconiosis will present with chronic fibrosis. Silicosis may include eggshell dystrophic calcification. [14]
Microscopic Pathology
On microscopic histopathological analysis, anthrocytes, or dust-laden macrophages are characteristic findings of coal worker’s pneumoconiosis. Onion skin lesions with concentrically arranged fibers and a central acellular area are typical of silicosis. In asbestosis, asbestosis bodies appear. Finally, ferruginous bodies are typical for inhalation of inorganic dust with deposition of ferrous materials. [14] [13] [15]
References
- ↑ 1.0 1.1 Farzaneh MR, Jamshidiha F, Kowsarian S (2010). “Inhalational lung disease”. Int J Occup Environ Med. 1 (1): 11–20. PMID 23022777.
- ↑ Yang M, Wang D, Gan S, Fan L, Cheng M, Yu L; et al. (2020). “Increasing incidence of asbestosis worldwide, 1990-2017: results from the Global Burden of Disease study 2017”. Thorax. 75 (9): 798–800. doi:10.1136/thoraxjnl-2020-214822. PMID 32467338 Check
|pmid=value (help). - ↑ 3.0 3.1 Castranova V, Vallyathan V (2000). “Silicosis and coal workers’ pneumoconiosis”. Environ Health Perspect. 108 Suppl 4: 675–84. PMC 1637684. PMID 10931786.
- ↑ Lapp NL (1981). “Lung disease secondary to inhalation of nonfibrous minerals”. Clin Chest Med. 2 (2): 219–33. PMID 6273058.
- ↑ Merget R, Bauer T, Küpper HU, Philippou S, Bauer HD, Breitstadt R; et al. (2002). “Health hazards due to the inhalation of amorphous silica”. Arch Toxicol. 75 (11–12): 625–34. doi:10.1007/s002040100266. PMID 11876495.
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help). - ↑ Li J, Yao W, Hou JY, Zhang L, Bao L, Chen HT; et al. (2018). “The Role of Fibrocyte in the Pathogenesis of Silicosis”. Biomed Environ Sci. 31 (4): 311–316. doi:10.3967/bes2018.040. PMID 29773095.
- ↑ Boitelle A, Gosset P, Copin MC, Vanhee D, Marquette CH, Wallaert B; et al. (1997). “MCP-1 secretion in lung from nonsmoking patients with coal worker’s pneumoconiosis”. Eur Respir J. 10 (3): 557–62. PMID 9072984.
- ↑ Vanhée D, Gosset P, Boitelle A, Wallaert B, Tonnel AB (1995). “Cytokines and cytokine network in silicosis and coal workers’ pneumoconiosis”. Eur Respir J. 8 (5): 834–42. PMID 7656959.
- ↑ Tjoe E, Borm P, Hohr D and Heederik D (2002).”Pneumoconiosis and Exposure to Quartz-containing Dust in the Construction Industry”. British Occupational Hygiene Society. Vol. 46, Supplement 1, pp. 71–75.
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID <286: https://doi.org/10.1002/1097-0274(200103)39:3<286: Check
|pmid=value (help). - ↑ 13.0 13.1 Fujimura N (2000). “Pathology and pathophysiology of pneumoconiosis”. Curr Opin Pulm Med. 6 (2): 140–4. doi:10.1097/00063198-200003000-00010. PMID 10741774.
- ↑ 14.0 14.1 Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS (2006). “Pneumoconiosis: comparison of imaging and pathologic findings”. Radiographics. 26 (1): 59–77. doi:10.1148/rg.261055070. PMID 16418244.
- ↑ Cohen RA, Petsonk EL, Rose C, Young B, Regier M, Najmuddin A; et al. (2016). “Lung Pathology in U.S. Coal Workers with Rapidly Progressive Pneumoconiosis Implicates Silica and Silicates”. Am J Respir Crit Care Med. 193 (6): 673–80. doi:10.1164/rccm.201505-1014OC. PMC 4824937. PMID 26513613.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Pneumoconiosis is caused by the inhalation of airborne dust and fibers that are either organic or inorganic. The specific cause depends on the specific pneumoconiosis. [1]
Causes
Common Causes
Common causes of pneumoconiosis may include: [2] [3] [4]
- Silicosis – silica
- Coalworker’s pneumoconiosis
- Asbestosis – asbestos fibers
- Berylliosis – beryllium dust
Less Common Causes
Less common causes of pneumoconiosis include: [2] [3] [4] [5]
- Talcosis – talc
- Siderosis – iron
- Hard metal pneumoconiosis
- Byssinosis – cotton
References
- ↑ Farzaneh MR, Jamshidiha F, Kowsarian S (2010). “Inhalational lung disease”. Int J Occup Environ Med. 1 (1): 11–20. PMID 23022777.
- ↑ 2.0 2.1 Stark P, Jacobson F, Shaffer K (1992). “Standard imaging in silicosis and coal worker’s pneumoconiosis”. Radiol Clin North Am. 30 (6): 1147–54. PMID 1410305.
- ↑ 3.0 3.1 Baur X, Woitowitz HJ, Budnik LT, Egilman D, Oliver C, Frank A; et al. (2017). “Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update”. Am J Ind Med. 60 (5): 411–421. doi:10.1002/ajim.22709. PMID 28409857.
- ↑ 4.0 4.1 Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS (2006). “Pneumoconiosis: comparison of imaging and pathologic findings”. Radiographics. 26 (1): 59–77. doi:10.1148/rg.261055070. PMID 16418244.
- ↑ Zuskin E, Valić F, Kanceljak B, Mustajbegović J, Sarić M (1996). “[Byssinosis–an occupational disease of textile workers]”. Lijec Vjesn. 118 (10): 248–53. PMID 9132525.
Differentiating Pneumoconiosis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Pneumoconiosis must be differentiated from other diseases that cause chronic cough and dyspnea.
Differentiating Pneumoconiosis from other Diseases
Pneumoconiosis must be differentiated from other diseases that cause cough and dyspnea.
Differentiating pneumoconiosis from other diseases on the basis of dyspnea and cough
On the basis of cough and chronic dyspnea, pneumoconiosis must be differentiated from lung malignancy, tuberculosis, emphysema, asthma, interstitial lung disease, pneumonia, and sarcoidosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22]
References
- ↑ Cotes JE, Field GB (1972). “Lung gas exchange in simple pneumoconiosis of coal workers”. Br J Ind Med. 29 (3): 268–73. doi:10.1136/oem.29.3.268. PMC 1009422. PMID 5044598.
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help). - ↑ Farzaneh MR, Jamshidiha F, Kowsarian S (2010). “Inhalational lung disease”. Int J Occup Environ Med. 1 (1): 11–20. PMID 23022777.
- ↑ Arakawa H, Johkoh T, Honma K, Saito Y, Fukushima Y, Shida H; et al. (2007). “Chronic interstitial pneumonia in silicosis and mix-dust pneumoconiosis: its prevalence and comparison of CT findings with idiopathic pulmonary fibrosis”. Chest. 131 (6): 1870–6. doi:10.1378/chest.06-2553. PMID 17400659.
- ↑ Stark P, Jacobson F, Shaffer K (1992). “Standard imaging in silicosis and coal worker’s pneumoconiosis”. Radiol Clin North Am. 30 (6): 1147–54. PMID 1410305.
- ↑ Cox CW, Rose CS, Lynch DA (2014). “State of the art: Imaging of occupational lung disease”. Radiology. 270 (3): 681–96. doi:10.1148/radiol.13121415. PMID 24568704.
- ↑ “StatPearls”. 2021. PMID 29493979.
- ↑ Balla MM, Desai S, Purwar P, Kumar A, Bhandarkar P, Shejul YK; et al. (2016). “Differential diagnosis of lung cancer, its metastasis and chronic obstructive pulmonary disease based on serum Vegf, Il-8 and MMP-9”. Sci Rep. 6: 36065. doi:10.1038/srep36065. PMC 5095766. PMID 27811960.
- ↑ Restrepo CS, Katre R, Mumbower A (2016). “Imaging Manifestations of Thoracic Tuberculosis”. Radiol Clin North Am. 54 (3): 453–73. doi:10.1016/j.rcl.2015.12.007. PMID 27153783.
- ↑ Loddenkemper R, Lipman M, Zumla A (2015). “Clinical Aspects of Adult Tuberculosis”. Cold Spring Harb Perspect Med. 6 (1): a017848. doi:10.1101/cshperspect.a017848. PMC 4691808. PMID 25659379.
- ↑ “StatPearls”. 2021. PMID 29489292.
- ↑ Price DB, Yawn BP, Jones RC (2010). “Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care”. Mayo Clin Proc. 85 (12): 1122–9. doi:10.4065/mcp.2010.0389. PMC 2996146. PMID 21123639.
- ↑ Khalili M, Wong RJ (2018). “Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net”. Dig Dis Sci. 63 (12): 3250–3252. doi:10.1007/s10620-018-5316-9. PMC 6436636. PMID 30311153.
- ↑ Ullmann N, Mirra V, Di Marco A, Pavone M, Porcaro F, Negro V; et al. (2018). “Asthma: Differential Diagnosis and Comorbidities”. Front Pediatr. 6: 276. doi:10.3389/fped.2018.00276. PMC 6178921. PMID 30338252.
- ↑ “StatPearls”. 2021. PMID 31082128.
- ↑ Prasse A (2016). “The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis”. Dtsch Arztebl Int. 113 (33–34): 565–74. doi:10.3238/arztebl.2016.0565. PMC 5015588. PMID 27598883.
- ↑ Ungprasert P, Ryu JH, Matteson EL (2019). “Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis”. Mayo Clin Proc Innov Qual Outcomes. 3 (3): 358–375. doi:10.1016/j.mayocpiqo.2019.04.006. PMC 6713839 Check
|pmc=value (help). PMID 31485575. - ↑ “StatPearls”. 2021. PMID 28613460.
- ↑ “StatPearls”. 2021. PMID 30020693.
- ↑ “StatPearls”. 2021. PMID 28613500.
- ↑ “StatPearls”. 2021. PMID 30252372.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
In 2010, a study indicated that pneumoconiosis accounted for 125,000 deaths worldwide, with 3495 attributed to asbestosis. Pneumoconiosis incidence has increased in workers that have been exposed to occupational dust. [1] [2]
Epidemiology and Demographics
Age
- The incidence of pneumoconiosis increases with age. [3]
Race
- Pneumoconiosis affects all races but African Americans have a higher rate of developing the condition when exposed to the same particles. [4]
Gender
- Males are more commonly affected by pneumoconiosis. [3]
Region
- Pneumoconiosis is one of the most common occupational diseases, especially in developing countries.
- In developed countries, asbestosis is the predominant pneumoconiosis whereas in developing countries it is either silicosis or coal worker’s pneumoconiosis. [5]
References
- ↑ Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J (2018). “Global Asbestos Disaster”. Int J Environ Res Public Health. 15 (5). doi:10.3390/ijerph15051000. PMC 5982039. PMID 29772681.
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ 3.0 3.1 Xie M, Liu X, Cao X, Guo M, Li X (2020). “Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017”. Respir Res. 21 (1): 49. doi:10.1186/s12931-020-1291-8. PMC 7014719 Check
|pmc=value (help). PMID 32046720 Check|pmid=value (help). - ↑ Cohen RA, Patel A, Green FH (2008). “Lung disease caused by exposure to coal mine and silica dust”. Semin Respir Crit Care Med. 29 (6): 651–61. doi:10.1055/s-0028-1101275. PMID 19221963.
- ↑ “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help).
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Risk factors for the development of pneumoconiosis depend on exposure, which is generally through certain occupations.
Risk Factors
Risk factors in the development of pneumoconiosis are occupational. [1] [2] [3] [4] [5] [6] [7]
Common Risk Factors
- Common risk factors in the development of pneumoconiosis include:
- Stonemasons, quarry workers, tunnellers, foundry, pottery workers (Silicosis)
- Construction workers
- Length of employment positively correlates
- Drilling
- Mining
- Sandblasting
- Concomitant smoking
- Textiles
- Shipbuilding
- Electronic shops
- Automotive industry
- Aerospace
Less Common Risk Factors
- Less common risk factors in the development of pneumoconiosis include:
- Environmental exposure in buildings
- Community-acquired in neighborhoods
References
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ Leung CC, Yu IT, Chen W (2012). “Silicosis”. Lancet. 379 (9830): 2008–18. doi:10.1016/S0140-6736(12)60235-9. PMID 22534002.
- ↑ “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help). - ↑ Perlman DM, Maier LA (2019). “Occupational Lung Disease”. Med Clin North Am. 103 (3): 535–548. doi:10.1016/j.mcna.2018.12.012. PMID 30955520.
- ↑ Infante PF, Newman LS (2004). “Beryllium exposure and chronic beryllium disease”. Lancet. 363 (9407): 415–6. doi:10.1016/S0140-6736(04)15523-2. PMID 14962519.
- ↑ Kreiss K, Wasserman S, Mroz MM, Newman LS (1993). “Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations”. J Occup Med. 35 (3): 267–74. PMID 8455096.
- ↑ Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS (1993). “Epidemiology of beryllium sensitization and disease in nuclear workers”. Am Rev Respir Dis. 148 (4 Pt 1): 985–91. doi:10.1164/ajrccm/148.4_Pt_1.985. PMID 8214955.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Screening for pneumoconiosis includes using chest radiography on workers exposed to certain particles as a part of preventative care. [1] [2]
Screening
Chest radiography is used as a screening tool for workers as a part of primary prevention. However, HRCT is more sensitive and specific. Future methods of screening workers include measuring serum SMRP and fibulin-3, CEA, and urinary 8-OHdG and breath testing of pentane, C5-C7 alkanes, and methylated alkanes. [3] [4] [5]
References
- ↑ “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help). - ↑ Perlman DM, Maier LA (2019). “Occupational Lung Disease”. Med Clin North Am. 103 (3): 535–548. doi:10.1016/j.mcna.2018.12.012. PMID 30955520.
- ↑ Yang HY (2019). “Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals”. PLoS One. 14 (4): e0214808. doi:10.1371/journal.pone.0214808. PMC 6448873. PMID 30946771.
- ↑ Remy-Jardin M, Remy J, Farre I, Marquette CH (1992). “Computed tomographic evaluation of silicosis and coal workers’ pneumoconiosis”. Radiol Clin North Am. 30 (6): 1155–76. PMID 1410306.
- ↑ Walkoff L, Hobbs S (2020). “Chest Imaging in the Diagnosis of Occupational Lung Diseases”. Clin Chest Med. 41 (4): 581–603. doi:10.1016/j.ccm.2020.08.007. PMID 33153681 Check
|pmid=value (help).
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Prognosis is generally poor, and mortality rates vary depending on the specific pneumoconiosis. For example, berylliosis patients mortality rates are between 6 to 35%. [1] [2]
Natural History, Complications, and Prognosis
Natural History
- The symptoms of pneumoconiosis typically develop 10-20 years after exposure to the specific particle, for example, silica in the case of silicosis. [2]
Complications
- Common complications of pneumoconiosis include: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12]
- Pulmonary fibrosis (accelerated by concomitant cigarette smoking)
- Emphysema
- COPD
- Pleural effusion
- Pleural plaques
- Malignant Mesothelioma (Asbestosis)
- Carcinoma
- Tuberculosis
- Scleroderma
- SLE
- Glomerulonephritis
- Pulmonary hypertension
- Cor pulmonale
- Respiratory failure
- Chronic necrotizing aspergillosis (Silicosis)
- Rheumatoid arthritis
- Chronic kidney disease
- Sarcoidosis
- Bronchitis
Prognosis
The prognosis for pneumoconiosis is poor and leads to respiratory complications and premature death. The prognosis is deemed to be poor particularly when fibrosis is found on CT scans. [2] [13] [14] Patients progress quickly to cor pulmonale and respiratory failure. In the case of silicosis, the survival is generally less than four years. [15] [16]
References
- ↑ PEYTON MF, WORCESTER J (1959). “Exposure data and epidemiology of the beryllium case registry, 1958”. AMA Arch Ind Health. 19 (2): 94–9. PMID 13616725.
- ↑ 2.0 2.1 2.2 “StatPearls”. 2021. PMID 32310362 Check
|pmid=value (help). - ↑ Fujimura N (2000). “Pathology and pathophysiology of pneumoconiosis”. Curr Opin Pulm Med. 6 (2): 140–4. doi:10.1097/00063198-200003000-00010. PMID 10741774.
- ↑ Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS (2006). “Pneumoconiosis: comparison of imaging and pathologic findings”. Radiographics. 26 (1): 59–77. doi:10.1148/rg.261055070. PMID 16418244.
- ↑ Cullinan P, Reid P (2013). “Pneumoconiosis”. Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
- ↑ Yew WW, Leung CC, Chang KC, Zhang Y, Chan DP (2019). “Can treatment outcomes of latent TB infection and TB in silicosis be improved?”. J Thorac Dis. 11 (1): E8–E10. doi:10.21037/jtd.2018.12.113. PMC 6384370. PMID 30863615.
- ↑ Blanco JJ, Barcala FJ, Moure MA, Mao MC (2011). “[Chronic necrotizing pulmonary aspergillosis as a complication of silicosis]”. An Sist Sanit Navar. 34 (1): 109–14. doi:10.4321/s1137-66272011000100013. PMID 21532653.
- ↑ Makol A, Reilly MJ, Rosenman KD (2011). “Prevalence of connective tissue disease in silicosis (1985-2006)-a report from the state of Michigan surveillance system for silicosis”. Am J Ind Med. 54 (4): 255–62. doi:10.1002/ajim.20917. PMID 20957678.
- ↑ Zaghi G, Koga F, Nisihara RM, Skare TL, Handar A, Rosa Utiyama SR; et al. (2010). “Autoantibodies in silicosis patients and in silica-exposed individuals”. Rheumatol Int. 30 (8): 1071–5. doi:10.1007/s00296-009-1116-z. PMID 19705119.
- ↑ Hertzberg VS, Rosenman KD, Reilly MJ, Rice CH (2002). “Effect of occupational silica exposure on pulmonary function”. Chest. 122 (2): 721–8. doi:10.1378/chest.122.2.721. PMID 12171857.
- ↑ Hnizdo E, Vallyathan V (2003). “Chronic obstructive pulmonary disease due to occupational exposure to silica dust: a review of epidemiological and pathological evidence”. Occup Environ Med. 60 (4): 237–43. doi:10.1136/oem.60.4.237. PMC 1740506. PMID 12660371.
- ↑ Tron V, Wright JL, Harrison N, Wiggs B, Churg A (1987). “Cigarette smoke makes airway and early parenchymal asbestos-induced lung disease worse in the guinea pig”. Am Rev Respir Dis. 136 (2): 271–5. doi:10.1164/ajrccm/136.2.271. PMID 2887135.
- ↑ Sahin H, Brown KK, Curran-Everett D, Hale V, Cool CD, Vourlekis JS; et al. (2007). “Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival”. Radiology. 244 (2): 591–8. doi:10.1148/radiol.2442060640. PMID 17641377.
- ↑ Walsh SL, Sverzellati N, Devaraj A, Wells AU, Hansell DM (2012). “Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants”. Eur Radiol. 22 (8): 1672–9. doi:10.1007/s00330-012-2427-0. PMID 22466512.
- ↑ Marchiori E, Ferreira A, Müller NL (2001). “Silicoproteinosis: high-resolution CT and histologic findings”. J Thorac Imaging. 16 (2): 127–9. doi:10.1097/00005382-200104000-00012. PMID 11292205.
- ↑ Marchiori E, Souza CA, Barbassa TG, Escuissato DL, Gasparetto EL, Souza AS (2007). “Silicoproteinosis: high-resolution CT findings in 13 patients”. AJR Am J Roentgenol. 189 (6): 1402–6. doi:10.2214/AJR.07.2402. PMID 18029877.
Diagnosis
Diagnosis
Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH

